SEC Filing Summary: Form 8-K
Business Context and Reporting Period
This filing is a Current Report (Form 8-K) dated May 26, 2011, submitted by AspenBio Pharma, Inc., a Colorado corporation. The report serves to disclose information under Regulation FD (Fair Disclosure) and includes a PowerPoint presentation as an exhibit. Note: The request metadata references "Riot Platforms, Inc.," but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document functions as a disclosure notice rather than a financial statement.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The report solely references the availability of a presentation dated May 2011.
Guidance, Outlook, and Risks
Management Commentary: The company has furnished a PowerPoint presentation (Exhibit 99.1) containing company information, which is incorporated by reference. The specific content of this presentation is not included in the filing text.
Risks and Contingencies: The filing text does not explicitly list risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the correct registrant name (AspenBio Pharma, Inc. vs. Riot Platforms, Inc.) to ensure data relevance.
- Access the referenced "Power Point Presentation" (Exhibit 99.1) on the company's website to obtain the actual financial data and strategic outlook.
- Confirm the date of the presentation (May 2011) to assess the timeliness of the information.
- Review the signature block to confirm authorization by the Chief Financial Officer, Jeffrey G. McGonegal.